First human trial launches for potential cardiometabolic treatment

NCT ID NCT06336005

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a new medicine, NNC6022-0001, for the first time in humans. It aims to check the drug's safety, how the body processes it, and how it works. Healthy adults aged 18-55 will receive either a single dose of the drug or a placebo. The results will help decide if further testing in patients is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NNC6022-0001

What this could lead to

If successful, this could pave the way for a new treatment option for cardiometabolic diseases like heart disease or diabetes.

What could go wrong

This is a very early, small study in healthy volunteers, so it may not show the hoped-for effects or could reveal safety issues. Many early-stage drugs do not advance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON - location Groningen

    Groningen, 9728 NZ, Netherlands